Condition: Nasopharyngeal Cancinoma (NPC) · SBRT · Immunotherapy · Sponsor: The First Affiliated Hospital of Xiamen University
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by Tislelizumab in patients with recurrent/metastatic nasopharyngeal carcinoma who have experienced oligoprogression (1-5 metastatic lesions) after immunotherapy.
This description comes directly from the study's public registry record.
San-Gang Wu, MD., PHD · 865922139531 · wusg@xmu.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Enrolling By Invitation |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06676722